New PD-1 Blocker For Cutaneous Squamous Cell Carcinoma

While the vast majority of patients with cutaneous squamous cell carcinoma (CSCC) are cured with surgery, approximately 5% develop advanced disease. Currently there are no systemic therapies approved for treatment of advanced CSCC, and most patients receive palliative care. Because CSCC occurs commonly in immunosuppressed patients and is associated with a high tumor mutation burden, […]

Read More

Multiple Oncology/Hematology Indications Recommended by EMA in June

On 28 June 2018, the European Medicines Agency (EMA) issued positive opinions for approval of several new anticancer therapies in Europe.   Neratinib for Extended Adjuvant Therapy in HER2-Positive, HR-Positive Early Breast Cancer. The EMA granted a positive opinion to pan-HER targeted tyrosine kinase inhibitor neratinib (Nerlynx®, Puma) for use as an extended adjuvant therapy […]

Read More

Enzalutamide: New Treatment for Nonmetastatic CRPC

Prior to this year, there were no approved treatment options for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), and the majority continued to receive androgen deprivation therapy (ADT) alone, despite limited benefit. In these patients, a rapidly rising prostate specific antigen (PSA) level is associated with a higher risk of metastasis and shorter survival. The […]

Read More

Anti-BCMA CAR T Cells Therapy Active in Pretreated Multiple Myeloma

Despite significant advances in the treatment of multiple myeloma (MM) and substantial improvement in survival in the past decade, it remains an incurable disease. Patients with relapsed MM who are double refractory to proteasome inhibitors and immunomodulatory drugs (IMiDs), or who have relapsed after ≥3 prior therapies, have a median survival of 8 months. Chimeric […]

Read More

Combo Improves Outcomes in Waldenström Macroglobulinemia

Adding Ibrutinib to Rituximab Improves PFS Over Rituximab Alone Waldenström macroglobulinemia (WM) is an uncommon plasma-cell disorder, characterized by overproduction of serum immunoglobulin M (IgM). While there is no standard of care for WM, the anti-CD20 monoclonal antibody rituximab is a common treatment for both treatment-naïve and previously treated patients. Furthermore, based on results from […]

Read More

RET Inhibitor LOXO-292 Shows Promise in Phase I Trial

Alterations in the oncogene RET occur in several solid tumors, including non-small cell lung cancer (NSCLC), thyroid cancer, and pancreatic cancer. Unfortunately, previous attempts to target these alterations with multikinase inhibitors have failed. LOXO-292 is a potent and highly selective RET inhibitor that has demonstrated high activity against RET-altered tumors in both in vitro and […]

Read More

FDA Expands Arsenal of Oncology/Hematology Medicines in June

New BRAF/MEK Inhibitor Combo in Melanoma. The Food and Drug Administration (FDA) approved the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib (Braftovi® and Mektovi®, Array BioPharma Inc) for the treatment of patients with metastatic melanoma with a BRAF V600E or V600K mutation. This approval was based on results from the phase […]

Read More